News Lilly forges a $415m ALS alliance with UK biotech Alchemab Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.
R&D Turning drug development on its head In episode 98 of the pharmaphorum podcast , host Jonah Comstock and Alchemab CEO Young Kwon discuss innovative new routes to drug discovery
News Reaction to MSD's UK exit as government tries to renew talks The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face